PE-22-28

PE-22-28 is a short synthetic peptide derived from spadin, a naturally occurring peptide. It is being investigated for its potential to improve mood, reduce stress, and protect neurons from damage. In preclinical studies, PE-22-28 showed stronger inhibition of the TREK-1 channel than the parent compound spadin Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. This channel is linked to depression and neuroplasticity. Behavioral experiments in mice found that PE-22-28 reduced immobility in forced-swim tests and increased signs of new nerve cell growth after only four days of treatment Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. However, all evidence currently comes from animal studies; no human trials have been conducted.

Because no human data exist, the practical use of PE-22-28 is based on community experience rather than controlled research. It is commonly explored by subcutaneous injection in low-microgram amounts for short cycles [community protocol]. The lack of established dosing and safety information means it should be approached with caution.

PE-22-28 is proposed to work by blocking the TREK-1 potassium channel, a protein that influences nerve cell excitability and mood regulation Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. In cell studies, PE-22-28 inhibited TREK-1 far more potently than spadin, with an IC50 around 0.12 nM compared to 40–60 nM for spadin Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. By keeping these channels closed, the peptide may increase signaling in brain regions involved in mood and resilience.

In addition to direct channel inhibition, animal data suggest PE-22-28 triggers neuroplasticity. After four days of treatment, mice showed more new neurons in the hippocampus and higher levels of the synapse protein PSD-95 in the cortex Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. These changes are similar to those seen with other rapid-acting antidepressants. While these pathways are plausible for PE-22-28, they have not been directly verified for this specific peptide.

The documented effects of PE-22-28 come from animal studies only. In forced-swim tests, mice given the peptide spent less time immobile, a marker of antidepressant action Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. They also began eating sooner in a novel environment after four days of treatment, suggesting reduced anxiety or increased drive Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. In the brain, the peptide boosted markers of neuroplasticity: more new neurons in the hippocampus and more synaptic protein in the cortex Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity.

The peptide's effects lasted longer than spadin in these models, with behavioral changes still apparent up to 23 hours after dosing, whereas spadin effects faded by 7 hours Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. No human studies exist, so these findings should be viewed as early and preliminary. There is no evidence for cognitive enhancement or neuroprotection in humans, and claims about mood support are inferred from rodent experiments.

No standard human dosing protocol exists for PE-22-28 because it has never been formally tested in people. The protocols discussed below are based on patterns from related peptides and practitioner experience, not on clinical trial data.

Research protocols in animal studies have used injections into the body cavity or under the skin, with doses that produce behavioral effects within 30 minutes to a few days Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity+1. Human explorers typically start at low doses around 100–200 micrograms injected under the skin once daily for 1–2 weeks to gauge tolerability [community protocol]. After an initial assessment, doses may be increased to a range of 200–500 micrograms per day for a total cycle of 4–8 weeks [community protocol]. Some split the dose into twice-daily injections. The rationale is to allow gradual adaptation and detect any side effects early.

Because the peptide's activity in mice lasted nearly a full day, once-daily dosing is the most common approach Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. There is no evidence to support oral use or to define a maximum safe dose. Users are advised not to combine PE-22-28 with other unstudied peptides or medications without a careful, stepwise approach.

PE-22-28 is typically supplied as a dry powder in a vial. To prepare it for injection, the powder is dissolved in a sterile liquid, most commonly bacteriostatic water [community protocol]. After adding the liquid, gently swirl the vial; do not shake, as this can damage the peptide [community protocol]. The resulting solution should be clear and free of particles.

Store unopened vials in a freezer at -20°C and protect them from light. After mixing, keep the solution in the refrigerator at 2–8°C and use it within 2–4 weeks if made with bacteriostatic water, or within 7–14 days if made with sterile water for injection [community protocol]. Do not freeze and thaw reconstituted peptide repeatedly, as this may cause degradation. If you notice cloudiness, color change, or specks, discard the vial.

An interactive concentration calculator is available on this page to help with precise dosing; refer to that tool rather than performing manual calculations.

PE-22-28 acts on the brain, so it may interact with other substances that affect mood, alertness, or neuronal signaling. No formal interaction studies have been done in humans, so the following advice is based on precaution.

• Antidepressants: Combining PE-22-28 with SSRIs, SNRIs, or other antidepressants could amplify antidepressant effects but also raise the risk of overstimulation, anxiety, or sleep disruption. Start one medication at a time and monitor for agitation [theoretical].
• Stimulants: Caffeine, ADHD medications, or other stimulants may add to the peptide's potential activating effects. Reducing stimulant intake during initial trials is prudent [community protocol].
• Sedatives: Alcohol, benzodiazepines, and sleep aids might mask side effects and should be kept stable to assess the peptide's effect [theoretical].
• Ketamine and esketamine: Both ketamine and PE-22-28 enhance neuroplasticity pathways. Introducing them together could cause unpredictable effects; separate by at least a day if both are used [theoretical].
• Opioids: There is no direct evidence, so caution is warranted with opioid use.

Always introduce one new substance at a time and allow at least a week of observation before making further changes.

PE-22-28 is sometimes combined with other research peptides in an attempt to enhance neuroprotection or mood benefits. Common strategies include:

• With neurotrophic peptides (e.g., Cerebrolysin, Dihexa): These aim to amplify neuroplasticity. However, additive effects could increase risk of overstimulation, and attributing benefit becomes difficult [community protocol].
• With anti-inflammatory peptides (e.g., BPC-157): The goal is to address both inflammation and mood pathways. While theoretically complementary, no data confirm synergy.
• With sleep or calming peptides (e.g., DSIP): This might smooth out sleep disruption if PE-22-28 causes activation; the two would be taken at different times of day [community protocol].
• With nootropics (e.g., Semax, Selank): The risk is that multiple cognitive enhancers obscure what each is doing; it's best to try them individually first [community protocol].

Because all evidence for PE-22-28 is preclinical, stacking increases uncertainty. The least risky approach is to test PE-22-28 alone before considering any combination, and then add one new compound at a time with careful monitoring [practitioner consensus].

PE-22-28 is not approved by the FDA or any other regulatory agency as a medicine. It remains an investigational peptide with only animal data to support its potential Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. In the United States, it is not a scheduled controlled substance, but it cannot be lawfully marketed as a drug, dietary supplement, or food ingredient.

For athletes, PE-22-28 has not been explicitly named on the WADA Prohibited List, but it falls under the category of unapproved pharmacological substances and could be considered a violation [community protocol]. No anti-doping sanctions specific to PE-22-28 have been reported, but the lack of clarity means competitive athletes should avoid it.

Internationally, the compound is unlikely to have marketing authorization in any major country. Its legal status for import varies by jurisdiction and is often uncertain. Researchers who acquire it do so through chemical suppliers, not pharmacies [community protocol].

The safety profile of PE-22-28 is unknown in humans because no clinical trials have been conducted. All information is based on its mechanism and on patterns from related peptides.

The most likely side effects are those common to many centrally active substances: headache, nausea, fatigue, injection-site soreness, and changes in sleep or mood [community protocol]. Because PE-22-28 is stimulating in animal models, it may cause anxiety, irritability, or insomnia, especially at higher doses Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Some users experience sedation instead, and the response can vary between individuals.

More theoretical concerns include mood destabilization in people with bipolar disorder, a potential to lower seizure threshold, and unknown effects on heart rate or blood pressure [theoretical]. The peptide enhanced cell growth markers in the brain, which raises a theoretical cancer risk, though no such link has been established Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Because of these unknowns, it should not be used by pregnant or nursing women, children, or people with serious psychiatric conditions.

Monitoring should include tracking mood, sleep, and any new symptoms daily for the first few weeks. Baseline blood work (CBC, basic metabolic panel, and inflammation markers) is recommended before starting and after a cycle [community protocol].